Browse > Article
http://dx.doi.org/10.7314/APJCP.2016.17.1.51

Reversal of Multidrug Resistance in Mouse Lymphoma Cells by Extracts and Flavonoids from Pistacia integerrima  

Rauf, Abdur (Department of Geology, University of Swabi)
Uddin, Ghias (Institute of Chemical Sciences, University of Peshawar)
Raza, Muslim (State Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology)
Ahmad, Bashir (Center of Biotechnology and Microbiology, University of Peshawar)
Jehan, Noor (Department of Geology, University of Swabi)
Siddiqui, Bina S (Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi)
Molnar, Joseph (Department of Medical Microbiology and Immunobiology, Faculty of Medicine, University of Szeged)
Csonka, Akos (Department of Medical Microbiology and Immunobiology, Faculty of Medicine, University of Szeged)
Szabo, Diana (Department of Medical Microbiology and Immunobiology, Faculty of Medicine, University of Szeged)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.17, no.1, 2016 , pp. 51-55 More about this Journal
Abstract
Phytochemical investigation of Pistacia integerrima has highlighted isolation of two known compounds naringenin (1) and dihydrokaempferol (2). A crude extract and these isolated compounds were here evaluated for their effects on reversion of multidrug resistance (MDR) mediated by P-glycoprotein (P-gp). The multidrug resistance P-glycoprotein is a target for chemotherapeutic drugs from cancer cells. In the present study rhodamine-123 exclusion screening test on human mdr1 gene transfected mouse gene transfected L5178 and L5178Y mouse T-cell lymphoma cells showed excellent MDR reversing effects in a dose dependent manner. In-silico molecular docking investigations demonstrated a common binding site for Rhodamine123, and compounds naringenin and dihydrokaempferol. Our results showed that the relative docking energies estimated by docking softwares were in satisfactory correlation with the experimental activities. Preliminary interaction profile of P-gp docked complexes were also analysed in order to understand the nature of binding modes of these compounds. Our computational investigation suggested that the compounds interactions with the hydrophobic pocket of P-gp are mainly related to the inhibitory activity. Moreover this study s a platform for the discovery of novel natural compounds from herbal origin, as inhibitor molecules against the P-glycoprotein for the treatment of cancer.
Keywords
Pistacia integerrima; naringenin; dihydrokaempferol; multidrug resistance (MDR);
Citations & Related Records
연도 인용수 순위
  • Reference
1 Hsu KC, Chen YF, Lin SR, et al (2011). iGEMDOCK: a graphical environment of enhancing GEMDOCK using pharmacological interactions and post-screening analysis. BMC Bioinformatics, 12, 33.   DOI
2 Ismail M, Muhammad N, Mohani N, et al (2011). Pharmacognostic and phytochemical investigation of the stem bark of Pistacia integerrima Stew ex Brandis. J Med Plants Res, 5, 3891-5.
3 Jara GE, Vera DMA, Pierini AB (2013). Binding of modulators to mouse and human multidrug resistance P-glycoprotein. A computational study. J Molecular Graphics Modelling, 46, 10-21.   DOI
4 Jones P, George A (2004). The ABC transporter structure and mechanism: perspectives on recent research. Cellular Molecular Life Sciences CMLS, 61, 682-99.   DOI
5 Larkin A, O'Driscoll L, Kennedy S, et al (2004). Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: A prognostic study. Int J Cancer, 112, 286-94.   DOI
6 Leonard GD, Fojo T, Bates SE (2003). The role of ABC transporters in clinical practice. Oncologist, 8, 411-24.   DOI
7 Li X-Q, Li J, Shi S-B, et al (2008). Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy. Int J Biological Markers, 24, 230-7.
8 Li Y, Yuan H, Yang K, et al (2010). The structure and functions of P-glycoprotein. Current Med Chem, 17, 786-800.   DOI
9 Li Z, Wan H, Shi Y, et al (2004). Personal experience with four kinds of chemical structure drawing software: review on chemdraw, chemwindow, ISIS/Draw, and chemsketch. J Chem Informat Computer Sci, 44, 1886-90.   DOI
10 Lopez D, Martinez-Luis S (2014). Marine natural products with P-glycoprotein inhibitor properties. Marine drugs, 12, 525-46.   DOI
11 Praveen K, Yellamma K (2014). Insilco identification of suitable acetuylcholinesterase inhibitors from morinda citrifolia linn. with reference to alzheimer's disease. Int J Pharm Sci Res, 5, 5474.
12 Rauf A, Khan R, Raza M, et al (2015a). Suppression of inflammatory response by chrysin, a flavone isolated from Potentilla evestita Th. Wolf. In silico predictive study on its mechanistic effect. Fitoterapia, 103, 129-35.   DOI
13 Rauf A, Saleem M, Uddin G, et al (2015b). Phosphodiesterase-1 inhibitory activity of two flavonoids isolated from pistacia integerrima JL stewart Galls. Evidence-Based Complem Altern Med, 2015.
14 Rauf A, Uddin G, Khan H, et al (2015c). Anti-tumour-promoting and thermal-induced protein denaturation inhibitory activities of ${\beta}$-sitosterol and lupeol isolated from Diospyros lotus L. Natural Product Res, 1-3.
15 Robey RW, Polgar O, Deeken J, et al (2007). ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev, 26, 39-57.   DOI
16 Sakamoto A, Matsumaru T, Yamamura N, et al (2013). Quantitative expression of human drug transporter proteins in lung tissues: analysis of regional, gender, and interindividual differences by liquid chromatographytandem mass spectrometry. J Pharmaceutical Sci, 102, 3395-406.   DOI
17 Sarkadi B, Homolya L, Szakacs G, et al (2006). Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiological Rev, 86, 1179-236.   DOI
18 Szabo D, Molnar J (1997). The role of stereoselectivity of chemosensitizers in the reversal of multidrug resistance of mouse lymphoma cells. Anticancer Res, 18, 3039-44.
19 Szakacs G, Paterson JK, Ludwig JA, et al (2006). Targeting multidrug resistance in cancer. Nature Reviews Drug Discovery, 5, 219-34.   DOI
20 Trott O, Olson AJ (2010). Autodock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem, 31, 455-61.
21 Uddin G, Rauf A, Al-Othman AM, et al (2012a). Pistagremic acid, a glucosidase inhibitor from Pistacia integerrima. Fitoterapia, 83, 1648-52.   DOI
22 Uddin G, Rauf A, Arfan M, et al (2012b). Pistagremic acid a new leishmanicidal triterpene isolated from Pistacia integerrima Stewart. J Enzyme Inhibit Med Chem, 27, 646-8.   DOI
23 Uddin G, Rauf A, Rehman T, et al (2011). Phytochemical screening of Pistacia chinensis var. integerrima. Middle-East J Sci Res, 7, 707-11.
24 Visualizer DS (2005). Accelrys software inc. Discovery Studio Visualizer, 2.
25 Wallace AC, Laskowski RA, Thornton JM (1995). LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Rngineer, 8, 127-34.   DOI
26 Ahmad NS, Waheed A, Farman M, et al (2010). Analgesic and anti-inflammatory effects of Pistacia integerrima extracts in mice. J Ethnopharmacol, 129, 250-3.   DOI
27 Assaraf YG (2006). The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resistance Updates, 9, 227-46.   DOI
28 Berman HM, Westbrook J, Feng Z, et al (2000). The protein data bank. Nucleic Acids Res, 28, 235-42.   DOI
29 Bihorel S, Camenisch G, Lemaire M, et al (2007). Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar. Pharmaceutical Res, 24, 1720-8.   DOI
30 Brinkhuis M, Izquierdo MA, Baak J, et al (2002). Expression of multidrug resistance-associated markers, their relation to quantitative pathologic tumour characteristics and prognosis in advanced ovarian cancer. Analytical Cellular Pathol, 24, 17-23.   DOI
31 Cole S, Bhardwaj G, Gerlach J, et al (1992). Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science-New York Then Washington, 258, 1650-.   DOI
32 Cole SP, Deeley RG (2006). Transport of glutathione and glutathione conjugates by MRP1. Trends Pharmacological Sci, 27, 438-46.   DOI
33 Cornwell MM, Pastan I, Gottesman MM (1987). Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biological Chem, 262, 2166-70.
34 Damiani D, Tiribelli M, Calistri E, et al (2006). The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype. Haematologica, 91, 825-8.
35 Diestra JE, Condom E, Del Muro XG, et al (2003). Expression of multidrug resistance proteins P-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: biological and clinical implications. J Urol, 170, 1383-7.   DOI
36 Doyle LA, Yang W, Abruzzo LV, et al (1998). A multidrug resistance transporter from human MCF-7 breast cancer cells. Proceedings National Acad Sciences, 95, 15665-70.   DOI
37 Germann UA, Pastan I, Gottesman MM (1993). P-glycoproteins: mediators of multidrug resistance. Seminars Cell Biol, 4, 63-76.   DOI
38 Gottesman MM, Ambudkar SV (2001). Overview: ABC transporters and human disease. J Bioenergetics Biomembranes, 33, 453-8.   DOI
39 Gottesman MM, Fojo T, Bates SE (2002). Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Rev Cancer, 2, 48-58.   DOI
40 Guex N, Peitsch MC (1997). SWISS-MODEL and the Swiss-Pdb Viewer: an environment for comparative protein modeling. Electrophoresis, 18, 2714-23.   DOI
41 Hanwell MD, Curtis DE, Lonie DC, et al (2012). Avogadro: An advanced semantic chemical editor, visualization, and analysis platform. J. Cheminformatics, 4, 17.   DOI
42 He S-M, Li R, R Kanwar J, et al (2011). Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1). Current medicinal chemistry, 18, 439-81.   DOI